卖什么
Replacing organ transplant with an infusion
商业模式拆解
买家：谁掌握预算？
未核实Hospitals and transplant/hepatology centers and payers that treat end-stage liver failure (inferred; no product price or buyer stated).
触发点：什么让他们现在购买？
Shortage of donor organs: the site says only 1 in 33 end-stage patients receive a transplant, about 200,000 develop end-stage liver failure each year.
工作流：什么输入变成什么输出？
Liver regeneration by infusion of allogeneic stem-cell-derived hepatocytes as an alternative to liver transplant for late-stage liver disease; initial niche indications A1ATD and PKU, then NASH.
经济账：省了什么，怎么收费？
Pre-revenue therapeutics developer: scalable fully defined manufacturing and an exclusive Stanford license; claims an unlimited cell supply versus donor/cadaver hepatocytes. Funded by investors (Wefunder crowdfunding).
渠道：怎么接触到客户？
Allogeneic off-the-shelf cell product intended for on-demand distribution; not yet marketed (pipeline stage), company is raising via Wefunder.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2018 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.